Kanabidiol
(IUPAC) ime | |||
---|---|---|---|
2-[(1R,6R)-6-izopropenil-3-metilcikloheks-2-en-1-il]-5-pentilbenzen-1,3-diol | |||
Klinički podaci | |||
AHFS/Drugs.com | Internacionalno ime leka | ||
Identifikatori | |||
CAS broj | 13956-29-1 | ||
ATC kod | nije dodeljen | ||
PubChem[1][2] | 644019 | ||
DrugBank | none | ||
ChemSpider[3] | 24593618 | ||
UNII | 19GBJ60SN5 | ||
Hemijski podaci | |||
Formula | C21H30O2 | ||
Mol. masa | 314,46 | ||
SMILES | eMolekuli & PubHem | ||
| |||
Fizički podaci | |||
Tačka topljenja | 66 °C (151 °F) | ||
Tačka ključanja | 180 °C (356 °F) (Opseg: 160 °C-180 °C)[4] | ||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status | Plan II (Kanada) |
Kanabidiol (CBD) je kanabinoid prisutan u kanabisu. On je glavni sastojak biljke, koji sačinjava do 40% njenog ekstrakta.[5]
On pokazuje sedativno dejstvo u testovima na životinjama.[6] Neka istraživanja, međutim, indiciraju da CBD može da poveća budnost.[7] On može da umanji brzinu uklanjanja THC-a iz tela, verovatno putem ometanja metabolizma THC-a u jetri.
Pokazano je da omanjuje konvulzije, inflamaciju, anksioznost, i mučninu, kao i da inhibira rast ćelija kancera.[8] Nedavne studije su pokazale da je kanabidiol efektivan kao atipični antipsihotik u tretmanu šizofrenije.[9] Ispitivanja su takođe pokazala da olakšava simptome distonije.[10][11]
Novembera 2007. je objavljeno da CBD redukuje rast agresivnih ljudskih ćelija raka dojke in vitro i da umanjuje njihovu invazivnost.
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ McPartland, JM; Russo, EB (2001). „Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts?” (PDF). Journal of Cannabis Therapeutics 1 (3/4): 103–132.
- ↑ Grlić, Ljubiša (1962). „A comparative study on some chemical and biological characteristics of various samples of cannabis resin”. Bulletin on Narcotics (United Nations Office on Drugs and Crime) (3): 37–46.
- ↑ Pickens JT (1981). „Sedative activity of cannabis in relation to its delta'-trans-tetrahydrocannabinol and cannabidiol content”. British Journal of Pharmacology 72 (4): 649–56. PMC 2071638. PMID 6269680.
- ↑ Nicholson, AN; C Turner, BM Stone, and PJ Robson (June 2004). „Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults” (fee required). J Clin Psychopharmacol 24 (3): 305–13. DOI:10.1097/01.jcp.0000125688.05091.8f. ISSN 0271-0749. PMID 15118485. Arhivirano iz originala na datum 2011-07-18. Pristupljeno 2007-05-03.
- ↑ Mechoulam, R.; M. Peters, Murillo-Rodriguez (21 Aug 2007). „Cannabidiol - recent advances”. Chemistry & Biodiversity 4 (8): 1678–1692. DOI:10.1002/cbdv.200790147. PMID 17712814.[mrtav link]
- ↑ Zuardi, A.W; J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira, F.S. Guimarães (2006). „Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug” (PDF). Brazilian Journal of Medical and Biological Research 39 (4): 421–429. DOI:10.1590/S0100-879X2006000400001. PMID 16612464.
- ↑ Consroe, P.; Sandyk, R.; Snider, S. R. (1986). „Open label evaluation of cannabidiol in dystonic movement disorders”. The International journal of neuroscience 30 (4): 277–282. DOI:10.3109/00207458608985678. PMID 3793381.
- ↑ Snider, Stuart R.; Consroe, Paul (1985). „Beneficial and Adverse Effects of Cannabidiol in a Parkinson Patient with Sinemet-Induced Dystonic Dyskinesia”. Neurology (Suppl 1): 201.
- Erowid Compounds found in Cannabis sativa